A Phase 2 interventional study of Etonogestrel 68mg implant and Etonogestrel 68mg implant in Abnormal Uterine Bleeding and Dysmenorrhea, sponsored by Saskatchewan Health Authority - Regina Area. Withdrawn at 1 site in Canada. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Saskatchewan Health Authority - Regina Area · Phase 2, Interventional, and Treatment
The objective of this study is to assess the efficacy of an implantable etonogestrel device in reducing hysterectomy rate in patients with a failed endometrial ablation.
The researchers aim to determine whether use of etonogestrel implant in patients with failed endometrial ablation significantly decreases hysterectomy rate. Changes in pelvic pain and vaginal bleeding will be assessed. Time to hysterectomy will be examined.
The researchers hypothesize that treatment of failed endometrial ablation with etonogestrel implant will decrease pelvic pain and vaginal bleeding resulting in a significantly decreased need for hysterectomy.
95 studies on the registry are indexed under Metrorrhagia; 24 are open to participants now.
Browse Metrorrhagia studies →Saskatchewan Health Authority - Regina Area is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
The participants will receive an etonogestrel 68mg implant
Drug: Etonogestrel 68mg implant · Device: Etonogestrel 68mg implant
Implant will be inserted
Also known as: Nexplanon
Implant will be inserted
Also known as: Nexplanon
Hysterectomy
occurrence of hysterectomy
Time frame: Occurrence of hysterectomy will be documented any time during the 3 year follow up period
Vaginal bleeding
Pictorial Blood Loss Assessment Chart (PBAC) score, minimum score = 0mL, maximum score = n/a, higher score indicates higher menstrual blood loss
Time frame: PBAC score will be documented at baseline and 3, 6, 12, 18, 24, 30, and 36 months
Pelvic Pain
Assessment of pelvic pain using Visual Analogue Scale (VAS), minimum score = 0, maximum score = 10, higher score indicates more pain
Time frame: VAS will be documented at baseline and 3, 6, 12, 18, 24, 30, and 36 months
Time to Hysterectomy
Time from booking of hysterectomy to actual hysterectomy will be documented
Time frame: Time of hysterectomy will be documented any time during the 3 year follow up period
This study is withdrawn, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saskatchewan Health Authority - Regina Area